NewsBenzingaZai Lab、北米神経内分泌腫瘍学会シンポジウムにおいて、前治療歴のある進行性肺外神経内分泌癌患者で臨床的に意義のある持続的な抗腫瘍反応を示したZocilurtatug Pelitecanの第1b/2相試験の最新データを発表へ Zai Lab、北米神経内分泌腫瘍学会シンポジウムにおいて、前治療歴のある進行性肺外神経内分泌癌患者で臨床的に意義のある持続的な抗腫瘍反応を示したZocilurtatug Pelitecanの第1b/2相試験の最新データを発表へ Benzinga 2026.11.05 14:07 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide